Fda approves Cosela (trilaciclib) to reduce bone marrow inhibition caused by chemotherapy

Recently, the U.S. Food and Drug Administration (FDA) approved Cosela (trilaciclib) to reduce the rate of bone marrow inhibition caused by chemotherapy in patients with small cell lung cancer.
Cosela (trilaciclib) can help protect bone marrow cells from chemotherapy by inhibiting cell cycle protein-dependent kinase 4/6 (CDK 4/6).
are designed to kill cancer cells, but they can also damage normal tissue.
bone marrow is particularly vulnerable to chemotherapy.
bone marrow produces red blood cells, white blood cells, and plateplates.
bone marrow is damaged, the bone marrow produces fewer of these cells, leading to fatigue, increased risk of infection and bleeding, among other problems.
trilaciclib may help protect normal bone marrow cells from the harmful effects of chemotherapy.
For patients with broad-stage small cell lung cancer, protecting bone marrow function may make chemotherapy safer and enable them to complete treatment on time as planned," said Dr. Albert Deisseroth of the FDA's Center for Drug Evaluation and Research.
phase III randomized, double-blind, placebo-controlled study evaluated the efficacy of Trilaciclib in patients with broad-stage small cell lung cancer.
245 patients received intravenous Cosela or placebo before chemotherapy.
results showed that patients treated with Cosela were less likely to develop severe neutral granulocyte reduction than those receiving a placebo.
patients with severe neutral granulocyte reduction, on average, patients treated with Cosela had a shorter duration than those who received a placebo.